ポリADPリボースポリメラーゼ（PARP）阻害剤の世界市場レポート 2025年

ポリADPリボースポリメラーゼ（PARP）阻害剤の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR11.7％で146億7,000万米ドルに成長します。予測期間の成長は、適応症の拡大、個別化医療、バイオマーカー開拓、医療経済、新興国市場に起因すると考えられます。予測期間における主な動向には、精密医療、免疫療法の進歩、標的治療、創薬における人工知能、患者中心のヘルスケアなどがあります。

卵巣がん患者の増加は、ポリADPリボースポリメラーゼ（PARP）阻害剤市場拡大の原動力になると予測されます。卵巣がんは、片方または両方の卵巣を侵す悪性腫瘍であり、遺伝的素因、高齢化、環境暴露、ホルモンバランスの乱れなどの要因に影響されます。ポリADPリボースポリメラーゼ（PARP）阻害剤は、卵巣がん治療において重要な役割を果たし、特にBRCA変異を持つ患者のDNA修復機構を標的とすることで、合成致死を誘導し、腫瘍細胞の死滅を促進します。例えば、2022年2月に世界卵巣がん連合が発表したデータによると、卵巣がんは2020年に世界で313万人の女性に罹患し、2040年には42％増の440万人に達すると予測されています。さらに、卵巣がんに関連する死亡者数は同期間に51％増加し、2020年の207万人から2040年には313万人になると予測されています。その結果、卵巣がんの有病率の上昇は、ポリADPリボースポリメラーゼ（PARP）阻害剤市場の成長のカタリストとして機能します。

ポリADPリボースポリメラーゼ（PARP）阻害剤市場の大手企業は、特定の遺伝子変異を持つがん患者に対応するよう調整されたジェネリックPARP阻害剤の開発に注力しており、個別化された治療法を提供しています。ジェネリックPARP阻害剤は、ポリADPリボースポリメラーゼ（PARP）という酵素の活性を阻害することで機能します。例えば、インドの製薬会社ザイダス・ライフサイエンシズ社は、2024年3月にIBYRAブランドでオラパリブを発売しました。このPARP阻害剤は、乳がん、卵巣がん、前立腺がん、膵臓がんに多く見られる特定の遺伝子変異を標的とし、カスタマイズされた有効な治療レジメンを提供します。特に、HRD陽性またはBRACA遺伝子変異を有する患者にとって有利であり、オラパリブは病勢の進行を抑制し、患者の予後を向上させる。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場の成長率分析
• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場規模実績と成長, 2019-2024
• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI予測市場規模と成長, 2024-2029, 2034F
• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場（医薬品タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• タラゾパリブ
• ベリパリブ
• オラパリブ
• その他の薬物の種類
• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• その他の流通チャネル
• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場アプリケーション別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 卵巣がん
• 乳がん
• その他の用途
• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場、タラゾパリブのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がんに対するタラゾパリブ
• 卵巣がんに対するタラゾパリブ
• 前立腺がんに対するタラゾパリブ
• その他のがんに対するタラゾパリブ
• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場、ベリパリブのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん治療薬ベリパリブ
• 卵巣がんに対するベリパリブ
• 非小細胞肺がん（NSCLC）に対するベリパリブ
• 他のがんに対するベリパリブ
• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場、オラパリブのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん（Her2陰性）に対するオラパリブ
• 卵巣がん（BRCA遺伝子変異）に対するオラパリブ
• 前立腺がん（BRCA遺伝子変異陽性）に対するオラパリブ
• 膵臓がん（BRCA遺伝子変異）に対するオラパリブ
• その他のがんに対するオラパリブ
• 世界ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場、その他の薬剤タイプのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニラパリブ
• ルカパリブ
• ペンブロリズマブ（PARP阻害剤との併用療法）
• その他のPARP阻害剤（臨床試験中の新薬）

第7章 地域別・国別分析

• 世界のポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場（地域別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場（国別）、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場の競合情勢
• ポリADPリボースポリメラーゼ（PARP）阻害剤PARPI市場企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• AstraZeneca plc
• GlaxoSmithKline plc.
• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Ipsen Biopharmaceuticals Inc.
• Genentech Inc.
• BioMarin Pharmaceutical Inc.
• Seattle Genetics Inc.
• Medivation Inc.
• Myriad Genetics Inc.
• PharmaMar S.A.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ポリADPリボースポリメラーゼ（PARP）阻害剤2029年のPARPI市場- 最も新しい機会を提供する国
• ポリADPリボースポリメラーゼ（PARP）阻害剤2029年のPARPI市場- 最も新しい機会を提供するセグメント
• ポリADPリボースポリメラーゼ（PARP）阻害剤2029年のPARPI市場- 成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Poly ADP-ribose polymerase (PARP) inhibitors are a category of pharmacological agents that function by inhibiting the enzyme PARP, crucial for DNA repair processes. By blocking PARP, these inhibitors effectively target cancers with deficiencies in other DNA repair pathways, thereby preventing cancer cells from repairing damaged DNA and ultimately leading to their demise.

The primary drug types of PARP inhibitors include talazoparib, veliparib, olaparib, and others. Talazoparib, for instance, is a potent PARP inhibitor utilized in cancer therapy, disrupting DNA repair mechanisms within cancer cells. These drugs are distributed through various channels such as hospital pharmacies, online pharmacies, retail pharmacies, among others. They have demonstrated efficacy in treating ovarian cancer, breast cancer, and other malignancies, and are utilized by various end users including hospitals, homecare facilities, specialty clinics, and others.

The poly ADP-ribose polymerase (PARP) inhibitor market research report is one of a series of new reports from The Business Research Company that provides poly ADP-ribose polymerase (PARP) inhibitor market statistics, including poly ADP-ribose polymerase (PARP) inhibitor industry global market size, regional shares, competitors with a poly ADP-ribose polymerase (PARP) inhibitor market share, detailed poly ADP-ribose polymerase (PARP) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the poly ADP-ribose polymerase (PARP) inhibitor industry. This poly ADP-ribose polymerase (PARP) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The poly ADP-ribose polymerase (PARP) inhibitor market size has grown rapidly in recent years. It will grow from $8.39 billion in 2024 to $9.41 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to clinical research, regulatory approvals, market competition, drug combinations, and patient advocacy.

The poly ADP-ribose polymerase (PARP) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $14.67 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to expanded indications, personalized medicine, biomarker development, health economics, and emerging markets. Major trends in the forecast period include precision medicine, immunotherapy advancements, targeted therapies, artificial intelligence in drug discovery, and patient-centric healthcare.

The uptick in ovarian cancer cases is anticipated to be a driving force behind the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market. Ovarian cancer, a malignancy affecting one or both ovaries, is influenced by factors such as genetic predisposition, aging demographics, environmental exposures, and hormonal imbalances. Poly ADP-Ribose Polymerase (PARP) Inhibitors serve as a vital component in ovarian cancer therapy, targeting DNA repair mechanisms, especially in patients harboring BRCA mutations, thereby inducing synthetic lethality and augmenting tumor cell demise. For instance, data from the World Ovarian Cancer Coalition in February 2022 revealed that ovarian cancer affected 3.13 million women globally in 2020, with projections indicating a 42% surge to reach 4.4 million by 2040. Furthermore, ovarian cancer-related deaths are anticipated to climb by 51% over the same period, rising from 2.07 million in 2020 to 3.13 million in 2040. Consequently, the escalating prevalence of ovarian cancer acts as a catalyst for the growth of the poly ADP-ribose polymerase (PARP) inhibitor market.

Leading players in the poly ADP-ribose polymerase (PARP) inhibitor market are focusing on the development of generic PARP inhibitors, tailored to cater to cancer patients with specific genetic mutations, thus offering personalized treatment modalities. Generic PARP inhibitors function by inhibiting the activity of the enzyme poly ADP-ribose polymerase (PARP). For example, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Olaparib under the IBYRA brand in March 2024. This PARP inhibitor targets specific genetic mutations prevalent in breast, ovarian, prostate, and pancreatic cancers, providing a customized and efficacious treatment regimen. Particularly advantageous for patients with HRD-positive or BRACA mutations, Olaparib aids in postponing disease progression, thereby enhancing patient outcomes.

In June 2023, Ariceum Therapeutics GmbH, a Germany-based radiopharmaceutical company, acquired Theragnostics Ltd. for $41.5 million. This strategic acquisition bolstered Ariceum Therapeutics' radiopharmaceutical portfolio, granting access to novel PARP inhibitor radiation therapies. Theragnostics Ltd., a UK-based biotechnology company, specializes in the development of radio-labeled PARP inhibitors for both diagnostic and therapeutic applications in tumor management.

Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc.

North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The poly ADP-ribose polymerase (PARP) inhibitor market consists of revenues earned by entities by providing services such as diagnostic tests, clinical trials, consulting services, and patient support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The poly ADP-ribose polymerase (PARP) inhibitor market also includes sales of test kits, laboratory equipment, imaging systems, sample processing instruments, reagents, and chemicals. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Poly ADP-Ribose Polymerase (PARP) Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on poly adp-ribose polymerase (parp) inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for poly adp-ribose polymerase (parp) inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The poly adp-ribose polymerase (parp) inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Talazoparib; Veliparib; Olaparib; Other Drug Types
• 2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
• 3) By Application: Ovarian Cancer; Breast Cancer; Other Applications
• 4) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Talazoparib: Talazoparib For Breast Cancer; Talazoparib For Ovarian Cancer; Talazoparib For Prostate Cancer; Talazoparib For Other Cancers
• 2) By Veliparib: Veliparib For Breast Cancer; Veliparib For Ovarian Cancer; Veliparib For Non-Small Cell Lung Cancer (Nsclc); Veliparib For Other Cancers
• 3) By Olaparib: Olaparib For Breast Cancer (Her2-negative); Olaparib For Ovarian Cancer (Brca-mutated); Olaparib For Prostate Cancer (Brca-Mutated); Olaparib For Pancreatic Cancer (Brca-Mutated); Olaparib For Other Cancers
• 4) By Other Drug Types: Niraparib; Rucaparib; Pembrolizumab (Combination Therapy With Parp Inhibitors); Other Parp Inhibitors (Emerging Drugs In Clinical Trials)
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Characteristics

3. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Trends And Strategies

4. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Growth Analysis And Strategic Analysis Framework

• 5.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Growth Rate Analysis
• 5.4. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Total Addressable Market (TAM)

6. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Segmentation

• 6.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Talazoparib
• Veliparib
• Olaparib
• Other Drug Types
• 6.2. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.3. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ovarian Cancer
• Breast Cancer
• Other Applications
• 6.4. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.5. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Talazoparib For Breast Cancer
• Talazoparib For Ovarian Cancer
• Talazoparib For Prostate Cancer
• Talazoparib For Other Cancers
• 6.6. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Veliparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Veliparib For Breast Cancer
• Veliparib For Ovarian Cancer
• Veliparib For Non-Small Cell Lung Cancer (Nsclc)
• Veliparib For Other Cancers
• 6.7. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Olaparib For Breast Cancer (Her2-negative)
• Olaparib For Ovarian Cancer (Brca-mutated)
• Olaparib For Prostate Cancer (Brca-Mutated)
• Olaparib For Pancreatic Cancer (Brca-Mutated)
• Olaparib For Other Cancers
• 6.8. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Niraparib
• Rucaparib
• Pembrolizumab (Combination Therapy With Parp Inhibitors)
• Other Parp Inhibitors (Emerging Drugs In Clinical Trials)

7. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Regional And Country Analysis

• 7.1. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 8.1. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 9.1. China Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• 9.2. China Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 10.1. India Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 11.1. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• 11.2. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 12.1. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 13.1. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 14.1. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• 14.2. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 15.1. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• 15.2. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 16.1. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 17.1. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 18.1. France Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 19.1. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 20.1. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 21.1. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• 21.2. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 22.1. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 23.1. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• 23.2. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 24.1. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• 24.2. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 25.1. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• 25.2. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 26.1. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• 26.2. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 27.1. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 28.1. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• 28.2. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

• 29.1. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Overview
• 29.2. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Competitive Landscape And Company Profiles

• 30.1. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Competitive Landscape
• 30.2. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca plc
• 31.3. GlaxoSmithKline plc.
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Merck KGaA
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Daiichi Sankyo Company Limited
• 31.8. Eisai Co. Ltd.
• 31.9. Ipsen Biopharmaceuticals Inc.
• 31.10. Genentech Inc.
• 31.11. BioMarin Pharmaceutical Inc.
• 31.12. Seattle Genetics Inc.
• 31.13. Medivation Inc.
• 31.14. Myriad Genetics Inc.
• 31.15. PharmaMar S.A.

32. Global Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

34. Recent Developments In The Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market

35. Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market High Potential Countries, Segments and Strategies

• 35.1 Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Poly ADP-Ribose Polymerase (PARP) Inhibitor PARPI Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer